Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Detalles Bibliográficos
Autores principales: Yamashita, Toshinari, Masuda, Norikazu, Saji, Shigehira, Araki, Kazuhiro, Ito, Yoshinori, Takano, Toshimi, Takahashi, Masato, Tsurutani, Junji, Koizumi, Kei, Kitada, Masahiro, Kojima, Yasuyuki, Sagara, Yasuaki, Tada, Hiroshi, Iwasa, Tsutomu, Kadoya, Takayuki, Iwatani, Tsuguo, Hasegawa, Hiroki, Morita, Satoshi, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278203/
https://www.ncbi.nlm.nih.gov/pubmed/32513251
http://dx.doi.org/10.1186/s13063-020-04408-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278203/
https://www.ncbi.nlm.nih.gov/pubmed/32513251
http://dx.doi.org/10.1186/s13063-020-04408-w

Ejemplares similares